|
Variable
|
Overall [cases (%)]
|
High PNI group [cases (%)]
|
Low PNI group [cases (%)]
|
P value
|
|---|
|
Total
|
274
|
152 (55.5)
|
122 (44.5)
| |
|
Age (years)
|
|
≤ 60
|
189 (69.0)
|
112 (73.7)
|
77 (63.1)
|
0.061
|
|
> 60
|
85 (31.0)
|
40 (26.3)
|
45 (36.9)
| |
|
Sex
|
0.274
|
|
Male
|
156 (56.9)
|
91 (59.9)
|
65 (46.7)
| |
|
Female
|
118 (43.1)
|
61 (40.1)
|
57 (53.3)
| |
|
Baseline BMI (kg/m2)
|
0.154
|
|
< 18.5
|
28 (10.2)
|
11 (7.2)
|
17 (13.9)
| |
|
18.5–25.0
|
187 (68.2)
|
105 (69.1)
|
82 (67.2)
| |
|
> 25.0
|
59 (21.5)
|
36 (23.7)
|
23 (18.9)
| |
|
Hemoglobin (g/L)
|
< 0.001
|
|
< 90
|
42 (15.3)
|
11 (7.2)
|
31 (25.4)
| |
|
≥ 90
|
232 (84.7)
|
141 (92.8)
|
91 (74.6)
| |
|
Tumor location
|
< 0.001
|
|
Right-sided colon
|
103 (37.6)
|
44 (28.9)
|
59 (48.4)
| |
|
Left-sided colon
|
171 (62.4)
|
108 (71.1)
|
63 (51.6)
| |
|
Tumor size (cm)
|
< 0.001
|
|
≤ 4
|
140 (51.1)
|
91 (59.9)
|
49 (40.2)
| |
|
> 4
|
134 (48.9)
|
61 (40.1)
|
73 (59.8)
| |
|
Differentiation
|
0.962
|
|
Well/moderate
|
207 (75.5)
|
115 (75.7)
|
92 (75.4)
| |
|
Poor/undifferentiated
|
67 (24.5)
|
37 (24.3)
|
30 (24.6)
| |
|
T stage
|
0.754
|
|
T1–T2
|
12 (4.4)
|
6 (3.9)
|
6 (4.9)
| |
|
T3
|
121 (44.2)
|
70 (46.1)
|
51 (41.8)
| |
|
T4
|
141 (51.5)
|
76 (50.0)
|
65 (53.3)
| |
|
N stage
|
0.762
|
|
N1
|
189 (69.0)
|
106 (69.7)
|
83 (68.0)
| |
|
N2
|
85 (31.0)
|
46 (30.3)
|
39 (32.0)
| |
|
TNM stage
|
0.290
|
|
IIIA
|
10 (3.6)
|
6 (3.9)
|
4 (3.3)
| |
|
IIIB
|
202 (73.7)
|
117 (77)
|
85 (69.7)
| |
|
IIIC
|
62 (22.6)
|
29 (19.1)
|
33 (27.0)
| |
|
Preoperative serum CEA level (ng/mL)
|
0.031
|
|
≤ 5
|
159 (58.0)
|
97 (63.8)
|
62 (50.8)
| |
|
> 5
|
115 (42.0)
|
55 (36.2)
|
60 (49.2)
| |
|
Cycles of XELOX adjuvant chemotherapya
|
0.296
|
|
< 6
|
53 (19.3)
|
26 (17.1)
|
27 (22.1)
| |
|
6–8
|
221 (80.7)
|
126 (82.9)
|
95 (77.9)
| |
|
LMR
| |
|
≤ 4.00
|
144 (52.6)
|
59 (38.8)
|
85 (69.7)
|
< 0.001
|
|
> 4.00
|
130 (47.4)
|
93 (61.2)
|
37 (30.3)
| |
|
NLR
| |
|
≤ 2.05
|
134 (48.9)
|
90 (59.2)
|
44 (36.1)
|
< 0.001
|
|
> 2.05
|
140 (51.1)
|
62 (40.8)
|
78 (63.9)
| |
|
PLR
| |
|
≤ 142.99
|
134 (48.9)
|
102 (67.1)
|
32 (26.2)
|
< 0.001
|
|
> 142.99
|
140 (51.1)
|
50 (32.9)
|
90 (73.8)
| |
|
Postoperative metastasisb
|
53 (19.3)
|
22 (14.5)
|
31 (25.4)
|
0.024
|
|
Liver metastasis
|
21 (7.7)
|
9 (5.9)
|
12 (9.8)
|
0.231
|
|
Lung metastasis
|
12 (4.4)
|
5 (3.3)
|
7 (5.7)
|
0.331
|
|
Abdominopelvic metastasis
|
16 (5.9)
|
5 (3.3)
|
11 (9.0)
|
0.053
|
-
PNI prognostic nutritional index, BMI body mass index, TNM stage clinical tumor-node-metastasis stage, CEA carcinoembryonic antigen, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
-
aXELOX adjuvant chemotherapy was administrated as follow: oxaliplatin 130 mg/m2 administered intravenously on day 1 and capecitabine 1000 mg/m2 administered orally twice daily on days 1–14 for a 3-week cycle
-
bThe metastatic sites of 4 patients were not recorded
